Gossamer Bio (STU:4GB) Change In Inventory : €0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gossamer Bio Change In Inventory?

Gossamer Bio's change in inventory for the quarter that ended in Dec. 2024 was €0.0 Mil. It means Gossamer Bio's inventory stayed the same from Sep. 2024 to Dec. 2024 .

Gossamer Bio's change in inventory for the fiscal year that ended in Dec. 2024 was €0.0 Mil. It means Gossamer Bio's inventory stayed the same from Dec. 2023 to Dec. 2024 .

Gossamer Bio's Total Inventories for the quarter that ended in Dec. 2024 was €0.0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Gossamer Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.

Gossamer Bio Change In Inventory Historical Data

The historical data trend for Gossamer Bio's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Change In Inventory Chart

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

Gossamer Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Gossamer Bio Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Gossamer Bio (STU:4GB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Gossamer Bio's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Gossamer Bio's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Gossamer Bio's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	8.957
	=	0.00

Gossamer Bio Change In Inventory Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (STU:4GB) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

GOSS:USA 4GB:Germany

Address

3115 Merryfield Row, Suite 120, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio Headlines

No Headlines